China keeps benchmark lending rates steady for a seventh straight month despite weak economic data

China keeps benchmark lending rates steady for a seventh straight month despite weak economic data


BEIJING, CHINA – NOVEMBER 11: The national flag of China flies in front of the headquarters of the People’s Bank of China (PBOC) on November 11, 2025, in Beijing, China. The PBOC serves as the country’s central bank, overseeing monetary policy, financial regulation, and currency issuance. (Photo by Cheng Xin/Getty Images)

Cheng Xin | Getty Images News | Getty Images

China’s central bank kept its loan prime rates steady on Monday, even as the world’s second largest economy has seen weak economic data and an extended slump in its property sector.

The People’s Bank of China kept its 1-year and 5-year loan prime rates unchanged at 3% and 3.5% respectively, holding them for a seventh straight meeting, in line with a Reuters survey.

The 1-year rate acts as a benchmark for new loans, while the 5-year helps peg mortgage rates.

The PBOC’s decision comes amid downbeat economic data from China in November, including lower-than-expected retail sales and industrial output.

Retail sales rose 1.3% last month from a year earlier, sharply missing Reuters’ median forecast for a 2.8% growth, and slowing from 2.9% rise in the prior month.

Industrial production also missed expectations, climbing 4.8% in November from a year earlier compared with estimates for a 5% jump, and marking its weakest growth since August 2024.

China continues to reel from a protracted slump in its real estate sector. Investment in fixed assets, which includes property, contracted 2.6% over the January through November period compared with a year earlier, sharper than the 2.3% drop estimated by economists.

Prices of new homes also also continued to decline in November, showing persistent weakness in China’s property sector.

New home prices fell 1.2% in tier-1 cities including Beijing, Guangzhou and Shenzhen while resale home prices dropped 5.8% from a year earlier.

Earlier this month, China’s finance ministry said it planned to issue ultra-long-term special government bonds next year to fund construction of key projects and new infrastructure projects.

The country has been contending with deflationary pressures, and policymakers have vowed to “vigorously support the implementation of special actions to boost consumption.”

An interim trade deal with the Washington that saw a suspension of prohibitive levels of tariffs on Chinese exports, however, could boost shipments to the U.S. and help the country realize its “around 5%” economic growth target for 2025.

— CNBC’s Anniek Bao contributed to this report.



Source

Citi UK CEO: ‘Phenomenal’ market resilience is keeping recession risk at bay — for now
World

Citi UK CEO: ‘Phenomenal’ market resilience is keeping recession risk at bay — for now

Tiina Lee, the CEO of Citi U.K., expects global growth to remain resilient this year, telling CNBC that a “recessionary environment” is “not our base case.” Markets have continued to perform in an orderly way, despite the economic and geopolitical upheaval caused by the Iran conflict, which entered its 60th day on Tuesday, Lee said. […]

Read More
‘Draconian development’ in Meta-Manus deal draws the line in China’s AI race with the U.S.
World

‘Draconian development’ in Meta-Manus deal draws the line in China’s AI race with the U.S.

Manus was hailed by Chinese state media as the “next DeepSeek” soon after its launch in March 2025, months before the startup relocated to Singapore. Cheng Xin | Getty Images News | Getty Images BEIJING — China’s decision to block U.S. tech giant Meta‘s $2 billion acquisition of artificial intelligence startup Manus is being seen […]

Read More
Novartis CEO warns reality of Trump’s drug pricing policy will set in over ‘the next 18 months’
World

Novartis CEO warns reality of Trump’s drug pricing policy will set in over ‘the next 18 months’

Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients. “The longer-term implications are significant,” CEO Vas Narasimhan told CNBC’s Carolin Roth. Novartis is focused on getting European and Japanese governments to quickly change […]

Read More